National Survey of Real‐World Australian Treatment Patterns for Patients With Very‐Early‐To Intermediate‐Stage Hepatocellular Carcinoma
Cancer Medicine · 2025
DOI: 10.1002/cam4.70722 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, 2025. Verfasst von Stuart K Roberts und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Alfred Health, Alfred Health, Melbourne, Victoria, Australia. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Practice Patterns, Physicians'. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: AstraZeneca Australia.
Abstract (Originalsprache)
Background/Purpose of the Study The treatment landscape for very early to intermediate stage hepatocellular carcinoma (HCC) is rapidly evolving, with new data and treatments emerging in recent years. There is a lack of data on current patterns of management for very early to intermediate stage HCC in Australian clinical practice and the role of newly emerging treatment options.
Methods
Multidisciplinary specialists involved in HCC management ( N = 86) participated in one of six state‐based meetings across Australia. Specialists were surveyed on their preferred management approaches at key clinical decision points for four patient case studies ranging from very early to intermediate stage HCC.
Results
Preferred management strategies for each of the patient case studies were largely consistent with current Australian HCC recommendations in relation to surveillance, diagnosis, and treatment of HCC although the preferred initial treatment selection varied considerably within and between hepatologists and other craft groups. There was, however, growing interest in emerging treatments, including stereotactic ablative body radiotherapy (SABR) for early stage HCC and systemic treatments used as adjuvant therapy or in combination with locoregional therapy in early and intermediate‐stage HCC. However, many participants required more data on these treatment modalities before incorporating them into routine clinical practice.
Conclusion
The heterogeneity of (very) early to intermediate‐stage HCC patients and the increasing number of available treatment options means clinical decision‐making, including treatment selection, is becoming more complex and diverse. More data are required to define the role of SABR and systemic therapies in very early to intermediate stage HCC before being adopted as standard of care in Australia.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Gastroenterology, Alfred Health, Alfred Health, Melbourne, Victoria, Australia.
- Department of Medicine, Central Clinical School, Monash University, Melbourne, Australia.
- Associate Dean, Curtin Medical School, Curtin University, Bentley, Western Australia, Australia.
- Department of Gastroenterology, Launceston General Hospital, Launceston, Tasmania, Australia.
- Department of Gastroenterology, Royal Brisbane and Womens Hospital, Brisbane, Queensland, Australia.
- AW Morrow Gastroenterology and Liver Centre, Royal Prince Alfred Hospital, Sydney, NSW, Australia.
ORCID-Profile: Stuart K Roberts
Förderung
- AstraZeneca Australia
Zitieren
APA
Roberts, S. K., Majeed, A., Rasaratnam, K., Olynyk, J. K., Shackel, N., Wood, M., Strasser, S. I., & Wigg, A. (2025). National Survey of Real‐World Australian Treatment Patterns for Patients With Very‐Early‐To Intermediate‐Stage Hepatocellular Carcinoma. Cancer Medicine. https://doi.org/10.1002/cam4.70722
Vancouver
Roberts SK, Majeed A, Rasaratnam K, Olynyk JK, Shackel N, Wood M, et al. National Survey of Real‐World Australian Treatment Patterns for Patients With Very‐Early‐To Intermediate‐Stage Hepatocellular Carcinoma. Cancer Medicine. 2025. doi:10.1002/cam4.70722
BibTeX
@article{Roberts2025,
author = {Roberts, Stuart K and Majeed, Ammar and Rasaratnam, Kiran and Olynyk, John K and Shackel, Nicholas and Wood, Marnie and Strasser, Simone I and Wigg, Alan},
title = {National Survey of Real‐World Australian Treatment Patterns for Patients With Very‐Early‐To Intermediate‐Stage Hepatocellular Carcinoma},
journal = {Cancer Medicine},
year = {2025},
doi = {10.1002/cam4.70722}
}
EUVIMED